Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00570713 · ClinicalTrials.gov registry record · Phase 2
An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer
A Phase 2 study, sponsored by Morphotek.
- Completed
- Registry status
- Phase 2
- Development phase
- 155
- Enrollment target
NCT00570713: Completed Phase 2 study, sponsored by Morphotek.
NCT00570713 is a Phase 2 study that has completed, run by Morphotek. The registered enrollment target is 155 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (17% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00570713, a Phase 2 study, has completed, sponsored by Morphotek.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 155 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the activity of MORAb-009 when added to a standard regimen of gemcitabine in patients with previously untreated unresectable stage 3 or 4 pancreatic cancer.
Primary Outcome
This measure was defined as the time (in months) from the date of randomization to the date of death, whatever the cause. The primary endpoint was analyzed when 110 events (deaths) were observed. In the absence of death confirmation or for subjects alive at the time of analysis, the survival time will be censored at the date of the last study follow-up.
Interventions
- DRUG Placebo
- DRUG Gemcitabine
- DRUG MORAb-009
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 155 participants |
| Start Date | 2007-12 |
| Est. Completion | 2009-12 |
| Phase | Phase 2 |
What the finished NCT00570713 record still lists
NCT00570713 is an interventional study that assigns participants to a tested intervention. The registered 155 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (17% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00570713 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00570713 about?
NCT00570713 is a clinical study titled "An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer". The purpose of this study is to investigate the activity of MORAb-009 when added to a standard regimen of gemcitabine in patients with previously untreated unresectable stage 3 or 4 pancreatic cancer.
What is the current status of trial NCT00570713?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 155 participants. The study started on 2007-12. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00570713?
The interventions under investigation include: Placebo (DRUG), Gemcitabine (DRUG), MORAb-009 (DRUG).
Who is sponsoring clinical trial NCT00570713?
This trial is sponsored by Morphotek, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00570713's enrollment target sits among peer trials
155 448th of 2000 higher than 1,553 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03223610 · 155 participants · Phase 1
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
- NCT05072483 · 155 participants
Natural History Study of CADASIL
- NCT05086497 · 155 participants · NA
WBSI Guided Personalized Delivery of TTFields
- NCT05412069 · 155 participants · NA
Trial to Evaluate Fecobionics in Fecal Incontinence (FI) (NORMAL and ABNORMAL-FI)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia